107 Care management of heart failure in elderly patients in France. Results from the DEVENIR study
| Autor: | Christine Contre, Pierre Clerson, Alain Cohen Solal, Leurs Irina, Jean Francois Thebaut, Maxime Guenoun, Pascal Poncelet, Patrick Assyag |
|---|---|
| Jazyk: | angličtina |
| Předmět: |
Pediatrics
medicine.medical_specialty education.field_of_study Ejection fraction Digoxin business.industry Population Management of heart failure medicine.disease Eplerenone chemistry.chemical_compound chemistry Heart failure Internal medicine medicine Hospital discharge Spironolactone Cardiology and Cardiovascular Medicine education business medicine.drug |
| Zdroj: | Archives of Cardiovascular Diseases Supplements. (1):35-36 |
| ISSN: | 1878-6480 |
| DOI: | 10.1016/S1878-6480(10)70109-9 |
| Popis: | Rationale The part of elderly patients (pts) in heart failure (HF) population is growing. They might pose specific problems due to the greater proportion of HF with preserved LVEF, more frequent comorbidities or contra-indications to recommended HF treatment. Objectives to describe the care management of pts > 80-year treated for HF in France. Methods Cross sectional observational survey with retrospective collection of data at hospital discharge. Pts must have been diagnosed with CHF and have been hospitalised for CHF within the previous 18 months. Pts are classified according to the LVEF at hospital discharge. Results 412 French outhospital cardiologists entered 1 452 pts meeting the inclusion criteria. FEVG at hospital discharge was known for 1408 pts. 355 (25%) were more than 80-year-old. Management care at hospital discharge according to age and LVEF is detailed below. LVEF LVEF 40-50% LVEF > 50% Total Age>80 ACEI/ARB 84% 81% 80% 82% * BB 71% 67% 40% † , ‡ 62% * Loop diuretics 92% 85% 85% 88% Spironolactone/eplerenone 26% 20% 18% 22% * Digoxin 20% 15% 29% 21% * Calcium antagonists 10% 14% 37% † , ‡ 18% Anticoagulants 49% 45% 51% 49% * Age≤80 ACEI/ARB 93% 93% 85% † , ‡ 92% BB 79% 78% 76% 79% Loop diuretics 90% 82% 79% † , § 86% Spironolactone/eplerenone 35% 21% 25% † , § 30% Digoxin 16% 15% 16% 15% Calcium antagonists 9% 19% 21% † , § 13% Anticoagulants 42% 39% 39% 41% † p 50% and LVEF ‡ p 50% and LVEF between 40% and 50%; § : p * p 80 and ≤ 80 years old adjusted for LVEF. Conclusion BB, ACEI/ARB, spironolactone/eplerenone are less often prescribed in elderly patients contrasting with digoxin and anticoagulants prescription. These differences persist after adjustment on LVEF. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|